Predicting clinical response to IL23 antagonists using IL23 pathway biomarkers

摘要

The present invention hires a population of patients suffering from an IL23-mediated disease (eg, Crohn's disease) that is responsive to treatment with an anti-IL23 antagonist (eg, comprising an anti-IL23 antibody or antigen-binding fragment thereof). Related to the use of components of the IL23 pathway as biomarkers for activating or identifying, eg IL22, LCN2, and combinations thereof. The level of IL23 pathway biomarker that exceeds or falls below a predetermined threshold is, for example, (i) whether a patient with an IL23-mediated disease or disorder such as Crohn's disease is eligible for treatment with a therapeutic agent (eg, an anti-IL23 antibody) Or (ii) determine whether to initiate, withhold, or correct treatment with a particular drug, (iii) an IL23 mediated disease using a particular therapeutic agent It can be used to diagnose whether it is treatable or not treatable, or (iv) predict the outcome of treating an IL23-mediated disease with a particular therapeutic agent. [Selection] Figure 1